I’m publishing my blog a day early due to the long holiday weekend, and wow this has been quite a week in regulatory news.  The FDA approved the first CAR-T therapy, along with two new novel drugs, a new biosimilar, and a couple of supplemental approvals for new indications.  The FDA also sent two refuse-to-file[…]